43.70
price up icon7.61%   3.09
pre-market  プレマーケット:  45.49   1.79   +4.10%
loading
前日終値:
$40.61
開ける:
$41.65
24時間の取引高:
444.78K
Relative Volume:
0.99
時価総額:
$2.83B
収益:
$87.56M
当期純損益:
$-167.47M
株価収益率:
-18.68
EPS:
-2.34
ネットキャッシュフロー:
$-148.20M
1週間 パフォーマンス:
+8.92%
1か月 パフォーマンス:
+7.48%
6か月 パフォーマンス:
+1.39%
1年 パフォーマンス:
+58.97%
1日の値動き範囲:
Value
$41.00
$44.03
1週間の範囲:
Value
$40.20
$44.34
52週間の値動き範囲:
Value
$27.47
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
184
Name
Twitter
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

KYMR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KYMR
Kymera Therapeutics Inc
43.70 2.83B 87.56M -167.47M -148.20M -2.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-10 開始されました BTIG Research Buy
2024-12-06 開始されました BMO Capital Markets Market Perform
2024-12-02 アップグレード Wells Fargo Equal Weight → Overweight
2024-11-18 開始されました Stephens Overweight
2024-09-09 再開されました Leerink Partners Outperform
2024-08-26 アップグレード Wolfe Research Peer Perform → Outperform
2024-04-22 開始されました Oppenheimer Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
Jan 21, 2025

Stephens Reaffirms Overweight Rating for Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat

Jan 21, 2025
pulisher
Jan 21, 2025

Kymera announces expansion of KT-474 HS and AD phase 2 studies - MSN

Jan 21, 2025
pulisher
Jan 17, 2025

Kymera Therapeutics soars as Sanofi expands phase 2 trials - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Kymera Therapeutics (NASDAQ:KYMR) Trading Down 6.3%Time to Sell? - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Kymera Therapeutics (NASDAQ:KYMR) Provides Business Update and Preliminary Cash Balance for 2024 - Defense World

Jan 17, 2025
pulisher
Jan 16, 2025

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last? - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

How the (KYMR) price action is used to our Advantage - Stock Traders Daily

Jan 16, 2025
pulisher
Jan 16, 2025

JPMorgan Chase & Co. Acquires 95,547 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Jan 16, 2025
pulisher
Jan 15, 2025

Kymera Provides Pipeline Objectives for 2025, Stock Gains - MSN

Jan 15, 2025
pulisher
Jan 14, 2025

Kymera rises after presentation at the J.P. Morgan event - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutio - GuruFocus.com

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera stock surges on product pipeline update By Investing.com - Investing.com Canada

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments - Yahoo Finance

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera Therapeutics (NASDAQ:KYMR) Trading 6.4% HigherHere's Why - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera reports progress in immunology drug trials By Investing.com - Investing.com South Africa

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera Therapeutics Shares Surge Amid 2025 Strategy Unveil - TipRanks

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera reports progress in immunology drug trials - Investing.com India

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - The Manila Times

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera Unveils Ambitious 2025 Immunology Pipeline Plans with $850M Cash Runway - StockTitan

Jan 14, 2025
pulisher
Jan 09, 2025

Analysts Set Expectations for KYMR FY2029 Earnings - Defense World

Jan 09, 2025
pulisher
Jan 08, 2025

Stifel sustains Buy on Kymera stock amid TPD drug optimism By Investing.com - Investing.com UK

Jan 08, 2025
pulisher
Jan 08, 2025

Equities Analysts Set Expectations for KYMR FY2029 Earnings - MarketBeat

Jan 08, 2025
pulisher
Jan 07, 2025

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14 - The Manila Times

Jan 07, 2025
pulisher
Jan 07, 2025

Kymera Therapeutics to Present Strategic Roadmap at J.P. Morgan Healthcare Conference - StockTitan

Jan 07, 2025
pulisher
Jan 06, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells $130,635.75 in Stock - MarketBeat

Jan 06, 2025
pulisher
Jan 05, 2025

(KYMR) Trading Report - Stock Traders Daily

Jan 05, 2025
pulisher
Jan 02, 2025

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space - BioWorld Online

Jan 02, 2025
pulisher
Jan 01, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $53.88 Consensus Price Target from Brokerages - Defense World

Jan 01, 2025
pulisher
Dec 29, 2024

Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $53.88 - MarketBeat

Dec 29, 2024
pulisher
Dec 29, 2024

Vir Biotechnology (NASDAQ:VIR) & Kymera Therapeutics (NASDAQ:KYMR) Financial Contrast - Defense World

Dec 29, 2024
pulisher
Dec 28, 2024

Kymera Therapeutics (NASDAQ:KYMR) Receives “Outperform” Rating from Leerink Partners - Defense World

Dec 28, 2024
pulisher
Dec 27, 2024

Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal - Yahoo Finance

Dec 27, 2024
pulisher
Dec 27, 2024

Leerink Partners Reaffirms Outperform Rating for Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat

Dec 27, 2024
pulisher
Dec 26, 2024

Trading (KYMR) With Integrated Risk Controls - Stock Traders Daily

Dec 26, 2024
pulisher
Dec 24, 2024

Geode Capital Management LLC Sells 996 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Dec 24, 2024
pulisher
Dec 21, 2024

HighTower Advisors LLC Takes $494,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Dec 21, 2024
pulisher
Dec 20, 2024

BMO Capital Initiates Coverage of Kymera Therapeutics (KYMR) with Market Perform Recommendation - MSN

Dec 20, 2024
pulisher
Dec 17, 2024

BTIG Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - MSN

Dec 17, 2024
pulisher
Dec 17, 2024

State Street Corp Has $81.79 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Verition Fund Management LLC - Defense World

Dec 16, 2024
pulisher
Dec 15, 2024

(KYMR) Investment Analysis - Stock Traders Daily

Dec 15, 2024
pulisher
Dec 10, 2024

Kymera Therapeutics (NASDAQ:KYMR) Now Covered by BTIG Research - MarketBeat

Dec 10, 2024
pulisher
Dec 09, 2024

Two Sigma Advisers LP Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Dec 09, 2024
pulisher
Dec 09, 2024

Wellington Management Group LLP Has $218.59 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Dec 09, 2024
pulisher
Dec 09, 2024

Kymera Therapeutics (NASDAQ:KYMR) Research Coverage Started at BMO Capital Markets - Defense World

Dec 09, 2024
pulisher
Dec 07, 2024

Kymera: Protein Degradation Could Drive Dupixent-Like Value (NASDAQ:KYMR) - Seeking Alpha

Dec 07, 2024
pulisher
Dec 06, 2024

BMO Capital Markets Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

Thrivent Financial for Lutherans Takes $313,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Dec 06, 2024
pulisher
Dec 06, 2024

The Manufacturers Life Insurance Company Has $6.07 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Dec 06, 2024
pulisher
Dec 05, 2024

BMO sets Kymera Therapeutics target at $55, rates Market Perform By Investing.com - Investing.com Canada

Dec 05, 2024
pulisher
Dec 05, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is Redmile Group LLC's 5th Largest Position - MarketBeat

Dec 05, 2024

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
大文字化:     |  ボリューム (24 時間):